CalliFarma Therapeutics

CalliFarma Therapeutics is a pre-clinical stage biotechnology company dedicated to developing innovative small molecule therapies for difficult-to-treat cancers. The company leverages research originating from the Mayo Clinic, particularly focusing on targeting oncogenic drivers such as MYC. CalliFarma aims to address significant unmet needs in pediatric and adult oncology through its proprietary drug discovery efforts. Its lead programs are currently in the discovery and lead optimization phases, with a primary focus on neuroblastoma and other MYC-dependent malignancies. By inhibiting previously undruggable targets, CalliFarma seeks to provide new hope for patients with aggressive solid tumors.